脑静脉血栓（CVT）与高发病率和死亡率相关。我们的目标是阐明癌症合并 CVT (CA-CVT) 患者的特征、治疗和结果。对 2016-2019 年国家住院患者样本 (NIS) 数据库查询了初步诊断为 CVT 的患者。然后确定当前积极诊断为恶性肿瘤（CA-CVT）的患者。比较 CA-CVT 和 CVT 患者的人口统计学和合并症。亚组分析探讨了造血系统癌症和非造血系统癌症患者。探讨了中风的严重程度和治疗方法。研究的住院患者结果包括出院情况、住院时间和死亡率。2016 年至 2019 年间，6,140 名患者的主要诊断代码为 CVT，370 名患者 (6.0%) 患有并存恶性肿瘤。最常见的恶性肿瘤是造血系统恶性肿瘤（n=195，52.7%），其次是中枢神经系统恶性肿瘤（n=40，10.8%）、呼吸系统恶性肿瘤（n=40，10.8%）和乳腺恶性肿瘤（n=40，10.8%）。这些患者往往比非 CA-CVT 患者年龄更大，并且更有可能患有并存的合并症。 CA-CVT 患者在国际脑静脉和硬脑膜窦血栓形成风险评分研究 (ISCVT-RS) 中的严重程度评分较高，并发症也较多。在倾向评分匹配的队列中，住院患者的结果没有差异。出现 CVT 的患者中有 6% 发生恶性肿瘤，在尚未确定高凝状态的明确原因的情况下，应将其视为潜在的合并症。恶性肿瘤与较高的死亡率有关。尽管如此，在调整 CVT 的严重程度后，患有癌症相关 CVT 的住院患者的结局与非癌症患者相当，这表明与恶性肿瘤相关的死亡率增加可能是由于更严重的 CVT 状况所致。

Cerebral venous thrombosis (CVT) is associated with a high degree of morbidity and mortality. Our objective is to elucidate characteristics, treatments, and outcomes of patients with cancer and CVT (CA-CVT).The 2016-2019 National Inpatient Sample (NIS) database was queried for patients with a primary diagnosis of CVT. Patients with a currently active diagnosis of malignancy (CA-CVT) were then identified. Demographics and comorbidities were compared between CA-CVT and CVT patients. Subgroup analyses explored patients with hematopoietic cancer and non-hematopoietic cancers. Stroke severity and treatment were explored. Inpatient outcomes studied were discharge disposition, length of stay, and mortality.Between 2016 and 2019, 6,140 patients had a primary diagnosis code of CVT, and 370 (6.0%) patients had a coexisting malignancy. The most common malignancy was hematopoietic (n=195, 52.7%), followed by central nervous system (n=40, 10.8%), respiratory (n=40, 10.8%), and breast (n=40, 10.8%). These patients tended to be older than non-CA-CVT and were more likely to have coexisting comorbidities. CA-CVT patients had higher severity scores on the International Study of Cerebral Vein and Dural Sinus Thrombosis Risk Score (ISCVT-RS) and increased complications. In a propensity-score matched cohort, there were no differences in inpatient outcomes.Malignancy occurs in 6% of patients presenting with CVT and should be considered a potential comorbidity in instances where clear causes of hypercoagulabilty have not been identified. Malignancy was linked to higher mortality rates. Nonetheless, after adjusting for the severity of CVT, the outcomes for inpatients with cancer-associated CVT were comparable to those without cancer, indicating that the increased mortality associated with malignancy is probably due to more severe CVT conditions.